Introduction
============

Prior to the mid-1990s, the extreme similarity of human and chimpanzee protein sequences suggested that phenotypic differences were primarily due to differences in gene regulation ([@evaa125-B54]). The first definitive exception was a fixed loss-of-function genomic mutation unique to the human lineage, in the gene-encoding CMP-Neu5Ac hydroxylase (*CMAH*) ([@evaa125-B24]), an event mediated by an *Alu--Alu* fusion ([@evaa125-B43]). This mutation eliminated biosynthesis of the common mammalian sialic acid (Sia) *N*-glycolylneuraminic acid (Neu5Gc) and caused accumulation of its precursor *N*-acetylneuraminic acid (Neu5Ac), radically changing cell surface extracellular glycosylation throughout the body in the hominin lineage. The mutation was dated to \>2 Ma by multiple methods ([@evaa125-B25]; [@evaa125-B45]). Additional examples emerged a few years later, including the forkhead box protein P2 (*FOXP2)* ([@evaa125-B32], [@evaa125-B33]), a myosin heavy chain family member (*MHY1*6) ([@evaa125-B27]; [@evaa125-B92]), and examples of gene duplication followed by adaptive evolution ([@evaa125-B49]). Along with biomedical considerations ([@evaa125-B95]), such discoveries lead to sequencing of the chimpanzee genome ([@evaa125-B23]). There are now many more defined genetic differences between humans and our closest evolutionary cousins, involving not only gene expression ([@evaa125-B32]; [@evaa125-B34]; [@evaa125-B103]; [@evaa125-B18]; [@evaa125-B51]; [@evaa125-B26]; [@evaa125-B73]; [@evaa125-B10]) but also other distinct genomic changes ranging from massive (megabase) structural variation to differences in gene copy numbers, de novo genes, pseudogenization ([@evaa125-B68]; [@evaa125-B81]), human-accelerated regions in noncoding regions, and microRNA genes ([@evaa125-B31]; [@evaa125-B61]; [@evaa125-B53]; [@evaa125-B81]).

This study focuses on human genes involved in the biology of sialic acids. All living cells are covered with complex arrays of glycoconjugates, with sialic acids occupying the majority of terminal positions on such glycan chains in animals of the Deuterostome lineage (including echinoderms and vertebrates) ([@evaa125-B35]). These acidic, nine-carbon backbone amino-sugars play important roles in cell--cell and cell--matrix interactions, as well as in host--pathogen interactions ([@evaa125-B99]). The hominin-specific loss-of-function mutation in *CMAH* mentioned above eliminated biosynthesis of Neu5Gc, which was a target for selective cell recognition by various nonhuman pathogens and toxins ([@evaa125-B57]; [@evaa125-B59]; [@evaa125-B19]; [@evaa125-B30]; [@evaa125-B4]). It is reasonable to speculate that exogenous pathogen recognition could have initially driven the *CMAH* loss-of-function, generating a polymorphism as the recessive loss-of-function mutant allele rose in frequency. However, this deletion was then fixed in an ancestral hominin population ∼2--3 Ma ([@evaa125-B25]), possibly by directional selection against Neu5Gc via female immunity during reproduction, a mechanism demonstrated in vivo using transgenic mice that carry the same mutation in their *Cmah* gene as humans ([@evaa125-B38]). Given the likely timing of these events, we speculated that anti-Neu5Gc immunity of hominin females immunized against Neu5Gc by increased contact with Neu5Gc-rich vertebrate animal prey might have contributed to the origins of the genus *Homo* ∼2 Ma ([@evaa125-B105]; [@evaa125-B12]).

Early discovery of some additional human-specific changes affecting sialic acid biology ([@evaa125-B15]; [@evaa125-B8]; [@evaa125-B36]; [@evaa125-B91]; [@evaa125-B44]; [@evaa125-B67]) and system-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents ([@evaa125-B5]) suggested a possible "hotspot" in human sialic acid evolution ([@evaa125-B96]). With the availability of more human genomes ([@evaa125-B1]), a recent study showed the patterns of genetic variation of 55 sialic acid biology-related genes in modern human populations did not significantly deviate from neutral expectations and were in fact not significantly different among genes belonging to different functional categories ([@evaa125-B65]).

Sialic acid binding Ig-like lectin (Siglecs) are type I transmembrane proteins with an N-terminal immunoglobulin (Ig)-like-V-set domain that mediates sialic acid recognition, and a variable number of Ig-like-C-2 type domains ([@evaa125-B7]). Siglecs often have a cytoplasmic tail with one or more immunoreceptor tyrosine-based inhibitory motifs that can suppress immune cell activation. Alternatively, they can recruit adaptor proteins with immunoreceptor tyrosine-based activating motifs. Although Siglecs likely have multiple functions, one prominent role appears to be recognition of endogenous sialylated glycans as self-associated molecular patterns, suppressing reactions of innate immune cells against self ([@evaa125-B97]). Activating Siglecs have a positively charged arginine or lysine in their transmembrane domains that can recruit DAP12 and activate cellular immune responses against pathogens mimicking endogenous sialic acids ([@evaa125-B86]). CD33-related Siglecs are rapidly evolving and among this family, nine inhibitory (hSiglec-3 and hSiglec-5 to hSiglec-12) and two activating members (hSiglec-14 and hSiglec-16) have been characterized in humans. Recently, an article published from our group showed variable presence or absence of functional changes in the *CD33rSIGLEC* cluster in 26 mammalian species including great apes ([@evaa125-B52]).

With the availability of genomes from both living great apes ([@evaa125-B76]; [@evaa125-B106]; [@evaa125-B55]) and extinct archaic hominins ([@evaa125-B79]; [@evaa125-B62]; [@evaa125-B77]), we now systematically reassess the previous discoveries from multiple groups and also report on several new findings. Overall, we find that multiple complex changes in genes involving sialic acid biology beyond the initial *CMAH* mutation did indeed occur but are mostly confined to the *CD33rSIGLEC* gene cluster on chromosome 19 ([@evaa125-B7]), encoding CD33rSiglecs, prominent on innate immune cells ([@evaa125-B98]).

Overall, we found that multiple changes in the *CD33rSIGLEC* gene cluster are common in all human populations, postdate the common ancestor with the chimpanzee/bonobo lineage, but predate the common ancestor with Neanderthals and Denisovans. Such multiple complex changes in this gene cluster appear to be associated with altered expression of these genes, not just confined to innate immune cells, but also in other unexpected human cell types, some associated with diseases that appear to be uniquely human.

Materials and Methods
=====================

Genome Assembly and Identification of Variants across Humans and Great Apes
---------------------------------------------------------------------------

The great ape genome data (total number 147) for *CMAH* and *CD33rSIGLECs* were derived from three publications ([@evaa125-B76]; [@evaa125-B106]; [@evaa125-B28]; [@evaa125-B55]). These great ape genomes were mapped to human reference genome (GRCh37/hg19) retrieved from UCSC genome browser, using Burrows--Wheeler aligner and further processed with Picard tool to remove duplicates and variant were called using Genome-analysis toolkit. Moreover, the variants in variant call format of chimpanzee, bonobos, gorilla, and orangutan were visualized in integrative genome viewer with their respective reference genome (Pantro4, Gorgor3, and PonAbe2) and annotation file. All archaic hominins raw and processed files were obtained from the Max Planck Institute for Evolutionary Anthropology ([@evaa125-B79]; [@evaa125-B22]; [@evaa125-B77]; [@evaa125-B89]) ([http://cdna.eva.mpg.de/neandertal](http://cdna.eva.mpg.de)). Bed coordinates of *SIGLECs* and *CMAH* genes were provided for each human and ape lineage as supplemental (chimpanzee, gorilla, and orangutan) ([supplementary file 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Additionally, bed coordinates of additional polymorphism present in *CD33rSIGLECs* with allele frequency in great ape population were also provided as supplemental ([supplementary file 2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

Inference of Strong Archaic Natural Selection
---------------------------------------------

The genes involved in sialic acid biology (67 genes) were overlapped with regions displaying signatures of ancient selective sweeps ([@evaa125-B75]). The method used to identify these signatures of archaic selection relies on a hidden Markov model to detect extended regions in the genome where the Neanderthal and Denisovan lineages fall outside the human variation ([@evaa125-B62]; [@evaa125-B77]). This method can only detect events that occurred between the split of modern and archaic humans around 0.5 Ma ([@evaa125-B78]) and the split of modern human populations from each other around 0.2 Ma ([@evaa125-B84]). For events with a selective advantage of 0.5% or larger, with an origin of the beneficial mutation as old as 600,000 years ago, the false positive rate of the method is lower than 0.1% and its true positive rate is larger than 65% ([@evaa125-B75]). We also note that signals of positive selection are not detectable if the selection coefficient is smaller than 0.1%. The Ensembl database (release 82) ([@evaa125-B2]) was used to annotate each gene with hg19 coordinates from transcription start to transcription end. Furthermore, *L1CAM*, *PECAM*, *CMAH*, *SIGLEC13*, *SIGLEC16*, and *SIGLEC17* were excluded because they fall either in filtered regions not considered for the ancient sweep screen or could not be mapped to hg19 coordinates. As regulatory regions may also have been the target of positive selection, we extended the start and end coordinates 1 Mb upstream and downstream, respectively. If a neighboring gene was within 1 Mb, we only extended the coordinates until 5 or 1 kb from the transcription start or end of this neighboring gene. In order to test whether the lack of signatures of ancient selection is statistically significant, the candidate regions of ancient selection were randomly placed in the genome and the random placements of all regions were iterated 1,000 times, counting how often no overlap with genes involved in sialic acid biology was detected. The depletion in selection is not significant (356 sets never overlap; *P* value = 0.356).

Immunohistochemistry of Siglecs
-------------------------------

Paraffin sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol and Tris-buffered saline--Tween (TBST). Following this, endogenous binding sites and peroxidases were blocked with 1% bovine serum albumin/TBST and 0.3% H~2~O~2~/TBST. This was followed by blocking of endogenous biotin and then heat-induced antigen retrieval was performed in citrate buffer pH 6. Primary antibodies (mouse anti-Siglec-7 and Rabbit anti-Siglec-13) or mouse IgG were then overlaid at optimal dilutions, and slides were incubated overnight at 4 °C in a humid chamber. Specific binding was detected using a biotinylated anti-mouse or anti-rabbit (for Siglec-13), followed by Horseradish Peroxidase (HRP) streptavidin and then biotinyl tyramide enhancement and then HRP streptavidin. Substrate color was developed, and nuclei were counterstained with hematoxylin and the slides were aqueous mounted for viewing and digital photomicrography using an Olympus BH2 microscope with an Olympus magnafire camera.

Results
=======

Multiple Derived, Fixed, or Polymorphic Genomic *SIGLEC* Variants Are Present in All Modern Human Populations
-------------------------------------------------------------------------------------------------------------

[Table 1](#evaa125-T1){ref-type="table"} summarizes events and frequencies in human populations based on the 1000 Genomes Project data and compares these with archaic hominin and great ape genomes. All human genomic changes in CD33-related *SIGLEC*s (affecting 8 out of 13 members of this class of genes) were present across modern human populations. Genome-wide association studies identified a derived CD33-linked allele (rs3865444(A), rs12459419(T)) that is protective against late onset Alzheimer's disease ([@evaa125-B85]). The linked single-nucleotide polymorphism was found to be variable across human populations with highest frequency in native American populations (48%) and lowest in African populations (5%). The previously reported Alu-mediated human *SIGLEC13* deletion ([@evaa125-B101]) and *SIGLEC17* (Siglec-P3) pseudogenization due to Open reading frame disruption and mutation of a critical arginine residue in its V-set domain ([@evaa125-B101]) appear to be fixed in all humans. *SIGLEC12*, *SIGLEC14*, and *SIGLEC16* show polymorphic pseudogenization in variable frequencies across human populations, as detailed in [table 1](#evaa125-T1){ref-type="table"}. *SIGLEC12* also harbors a human-universal mutation of the critical arginine residues in the V-set domain (Arg -\> Cys, first V-set domain) abrogating its ability to recognize sialic acid. An additional *SIGLEC12* inactivation mutation (rs16982743) was found at an overall 18.6% frequency, highest in Africans (37%) and lowest in East Asians (5%). Another SIGLEC12 polymorphism, that is, frameshift (rs66949844) averages 59% (highest in native Americans and lowest in East Asians) in human population. Additionally, based on the two linked alleles present in *SIGLEC16* (rs12611411(T) and rs12984584(C)), the pseudogene variant (*SIGLEC16P*) is present in higher frequency than the functional allele (*SIGLEC16*) in human populations ([@evaa125-B100]). Because these SIGLEC clusters are undergoing multiple gene conversions, some regions are highly prone to low mapping quality and hence some variants are not well defined, for example, *SIGLEC14* fusion-deletion, which is highly prevalent in East Asian populations ([@evaa125-B108]; [@evaa125-B3]). Due to the lack of high coverage sequence data, these regions have not been well genotyped in nonhuman genomes. The *CMAH* exon deletion is confirmed to be universal to humans.

###### 

Detailed Description of Genomic Variants and Their Percentage in Each Lineage Based on *CD33rSIGLECs and CMAH* Genes

  Gene                Genomic Changes              Changes       1000 Genomes Data (%)   Archaic Genomes (%)   Great Apes                                                                                         
  ------------------- ----------------------- ----------------- ----------------------- --------------------- ------------ ----- ----------- ----------- ----------- ----------- ----------- -------------------- ------------
  *CD33m (SIGLEC3)*   rs12459419(T)                  TT                    5                     48                19       31       16       Ancestral      ND       Ancestral   Ancestral       Ancestral        Ancestral
  rs3865444(A)        AA                              5                   48                     19                31       16    Ancestral   Ancestral   Ancestral   Ancestral   Ancestral       Ancestral       
  *SIGLEC5*           Arg (R)/H                       R                   100                    100              100       100      100         100         100         R/H          R              R/H            Low call
  *SIGLEC12*          Arg (R)/C                       C                   100                    100              100       100      100         100         100          R           R               R                R
  −/C(rs66949844)     C                              60                   74                     37                67       63       50          100         ---         ---         ---             ---          
  Q/\*(rs16982743)    \*                             37                   13                      4                20       11       60          50           Q           Q           Q               Q           
  *SIGLEC13*          Deletion                       Del                  100                    100              100       100      100         100         100          0           0               0                0
  *SIGLEC14*          Arg (R)                         R                   100                    100              100       100      100         100         100         R/H         R/H             R/H           Low call/Y
  *SIGLEC14*          Deletion                 Fusion/deletion            30                     21                73       22       33          ND          ND          ND          ND               ND               ND
  *SIGLEC16*          rs12611411 rs12984584          16P                  83                     85                67       82       87          67          50       Ancestral   Ancestral   Not well annotated   Ancestral
  *SIGLEC17*          Arg (R)/W                       W                   100                    100              100       100      100         100         100          R           R               R                R
  G/-                 Disrupted ORF                  100                  100                    100              100       100      100         100          G           G           G               G           
  CMAH                Exon 6 deletion               CMAHP                 100                    100              100       100      100         100         100       Present     Present    Not well annotated    Present

[Note]{.smallcaps}.---All the genomic changes were found in all existing human populations. CD33m (Siglec-3):allele increasing alternate splice form protective against Alzheimer's disease; ND:not determined; Siglec-5: sialic acid binding arginine residue; Siglec-12: mutation of sialic acid binding arginine residue; Siglec-12: 1-bp insertion resulted in pseudogene (12P); Siglec-12: inactivation polymorphism at position 29 amino acid; Siglec-13: complete deletion by Alu--Alu fusion event; Siglec-14: sialic acid binding arginine residue; Siglec-14: 16-kb deletion/fusion, difficult to read from standard genomic data; Siglec-16:, pseudogene (16P) and gene (16) forms; Siglec-17: mutation of sialic acid binding arginine residue; Siglec-17: 1-bp deletion that disrupted the Open reading frame (ORF); CMAH: pseudogene due to 92-bp exon 6 deletion.

Great Ape Genomes Do Not Show a High Frequency of *SIGLEC* Gene Mutations
-------------------------------------------------------------------------

Our previous human--ape comparisons involved the incomplete draft of a single chimpanzee genome, a few additional incomplete great ape sequences and a small number of human genomes ([@evaa125-B23]). Thus, it remained possible that the genomic changes were actually a common feature of such genes across all these taxa. The availability of newly annotated versions of great ape genomes ([@evaa125-B76]; [@evaa125-B106]; [@evaa125-B28]; [@evaa125-B55]) now allows for much better control against ascertainment bias, by comparing human-specific polymorphisms with multiple different genomes for each ape species, capturing potential polymorphisms in the latter as well ([@evaa125-B93]). We observed that great ape genomes share none of the mutations observed in human populations. Instead, we only observed independent changes in critical arginine residues in V-set domain of *SIGLEC5/14,* rendering them unable to recognize sialic acids ([table 1](#evaa125-T1){ref-type="table"}). Although the essential arginine change (Arg -\> His) in *SIGLEC5* was found to be polymorphic in chimpanzee and gorilla, sequences in orangutan were not recognized due to low mappability. The *SIGLEC14* essential arginine change (Arg -\> His) was found to be polymorphic in chimpanzee, bonobo, and gorilla. However, sequences of *SIGLEC14* in orangutan were not determined in most of the species due to low coverage, except for one that harbors an essential arginine change to tyrosine (Arg -\> Tyr). The *CMAH* gene is functional in all great apes as expected, given that both types of sialic acids (Neu5Ac and Neu5Gc) are present in all these species ([@evaa125-B66]). Overall, human genomes harbored a far greater number of structural/functional changes in *CD33rSIGLEC* genes (see [fig. 1](#evaa125-F1){ref-type="fig"} and [supplementary file 2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

![Evolutionary changes in hominid *SIGLEC* genes. The tree represents phylogenetic relatedness among hominids and different types of genomic events are depicted according to the color codes. Siglec expression differences are based on more limited comparisons (see [table 1](#evaa125-T1){ref-type="table"} and [fig. 3](#evaa125-F3){ref-type="fig"} and see text for discussion).](evaa125f1){#evaa125-F1}

Most Human Lineage-Specific Mutations Are Also Found in Archaic Hominin Genomes
-------------------------------------------------------------------------------

To further understand the timing of these human genomic changes of these human genomic variants, we looked for their presence in archaic human genomes, that is, Neanderthal and Denisovan. The exon deletion leading to loss-of-function of the *CMAH* gene is shared by these two archaic genomes, as expected based on the existing estimates of fixation of the mutation over 2 Ma ([@evaa125-B43]). Notably, almost all other human *CD33rSIGLECs* variants (except for CD33-linked variants protective against late onset Alzheimer's disease) were also present in these archaic hominin genomes in variable frequency (listed in [table 1](#evaa125-T1){ref-type="table"} and [fig. 1](#evaa125-F1){ref-type="fig"}) placing their origin before the human--Neanderthal common ancestor (∼0.6 Ma) ([@evaa125-B78]; [@evaa125-B41]). Due to unavailability of well annotated sequences, the *SIGLEC14* fusion/deletion could not be determined in archaic hominins.

Lack of Evidence for Strong Selection up to 500,000 Years Ago
-------------------------------------------------------------

The presence of all genomic *SIGLEC* changes in human populations indicates that they predate the common ancestor of modern humans ∼0.2--0.3 Ma ([@evaa125-B48]). Consistent with this observation, the recent article by [@evaa125-B65] found that the patterns of genetic variation of most *CD33rSIGLEC* genes did not significantly deviate from neutral expectations, and the few that did significantly deviate from neutrality experienced either soft sweeps or population-specific hard sweeps ([@evaa125-B65]). Using a method that allows detection of selection in deeper time (∼0.5 Ma) ([@evaa125-B75]), we also found no evidence of strong selection after the ancestors of modern and archaic humans (Neanderthal--Denisovan) split from each other around 500,000 years ago. As selection may also target neighboring regulatory regions, we defined regulatory domains around each gene and looked for overlaps with candidate sweep regions. Using these extended gene coordinates, we again found no overlap with candidate regions for selective sweeps, suggesting that none of the genes involved in sialic acid biology exhibits strong signatures of selection more recently than 0.5 Myr in the common ancestral population of all modern humans. The description of extended lineage sorting (ELS) is provided in [figure 2](#evaa125-F2){ref-type="fig"}.

![Description of the ELS scan. (*A*) Illustration of the selection signature. Patterns of shared mutations (dots) were used to reconstruct the genealogy that relate an archaic human Altai Neanderthal ([@evaa125-B77]); or Denisovan ([@evaa125-B62]); top rectangle to modern humans (bottom rectangles) at any given position along their genomes. There are two types of genealogies: the archaic falls either outside the modern human variation (external genealogy) or inside (internal genealogy). The internal genealogy is the most frequent in the genome. However, if a mutation spread among the ancestors of modern humans (blue dot) more recently than the population split with the ancestors of archaic humans, the archaic will be expected to fall outside the modern human variation in the genomic region around the mutation that has not been unlinked by recombination (blue rectangles). This region is expected to be large if the mutation was positively selected and spread quickly in the population, not leaving enough time for recombination to break its linkage with other mutations (black dots). (*B*) Time scales for the signatures of selection in humans. The tree represents the simplified population history of Neanderthals, Denisovans, and modern humans ([@evaa125-B78]). The colors indicate the time scales investigated by the ELS scan (red) and other methods (blue) used to detect events of positive selection on the modern human lineage.](evaa125f2){#evaa125-F2}

Human-Specific Expression of CD33rSiglecs in Nonimmune Tissues
--------------------------------------------------------------

In addition to these multiple, polymorphic complex genomic changes in the human *CD33rSIGLEC* gene cluster, there appear to be unusual (derived) human-specific expression patterns of CD33rSiglecs (in nonhemopoietic cells) in locations such as placental trophoblast (*SIGLEC6*) ([@evaa125-B50]), ovarian fibroblasts (*SIGLEC11/16*) ([@evaa125-B102]), amniotic epithelium (*SIGLEC5/14*) ([@evaa125-B3]), and microglia (*SIGLEC11/16*) ([@evaa125-B44]). In each of the above instances, we have previously reported human-specific expression and lack of expression in chimpanzee tissue samples (in some instances also other available great ape tissues). With regard to the recent report of *SIGLEC7* expression in human pancreatic islets ([@evaa125-B107]), we now show that such expression is missing in chimpanzee pancreatic islets ([fig. 3](#evaa125-F3){ref-type="fig"}). We also found that Siglec-13, which is deleted in hominins, is highly expressed in chimpanzee intestinal epithelium and skin ([fig. 3](#evaa125-F3){ref-type="fig"}). Current and previously published data are summarized in [table 2](#evaa125-T2){ref-type="table"}. Although we obviously cannot detect tissue-specific expression in Neanderthals or Denisovans, it is reasonable to consider the possibility that these unusual human-specific expression patterns arose during the course of the large-scale changes affecting the *CD33rSIGLEC*s gene cluster during the proposed "hotspot" and would thus have already existed in both of those extinct relatives.

![Examples of immunohistochemistry using antibodies against Siglec-7 and Siglec-13 on human and chimpanzee tissues (see Materials and Methods for detail). (*A*) No difference in expression of Siglec-7 in splenic blood cells. There is markedly increased expression of Siglec-7 in human pancreatic islets. (*B*) Siglec-13 expression in chimpanzee skin and prostatic epithelium. The gene-encoding Siglec-13 is completely deleted in humans. Scale bars = 100 μm.](evaa125f3){#evaa125-F3}

###### 

Differential Tissue and Cell Type Expression Profile of *SIGLEC* Genes among Humans and Great Apes

  Siglecs     Humans                                            "Great Apes"                                                                Current Data and Literature Reference(s)                   Potential Relevance to Diseases That Appear Unique to Humans
  ----------- ------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------
  *CD33*      High expression in human brain microglia          Low expression in chimpanzee brain microglia                                [@evaa125-B85]                                             Alzheimer's disease
  Siglec-5    Selectively expressed in amniotic epithelium      Not expressed in chimpanzee amniotic epithelium                             [@evaa125-B3]                                              Intrauterine infections with group B *Streptococcus*
  Siglec-6    Selectively expressed in placental trophoblast    Not expressed in placental trophoblast chimpanzee, gorilla, and orangutan   [@evaa125-B16]                                             Preeclampsia
  Siglec-7    Selectively expressed in pancreatic islet cells   Not expressed in chimpanzee                                                 Present study ([fig. 3*A*](#evaa125-F3){ref-type="fig"})   Type I diabetes
  Siglec-11   Selectively expressed in brain microglia          Less expression in chimpanzee, no expression in orangutan brain             [@evaa125-B44]                                             *Escherichia coli* K1 meningitis in neonates and infants
  Siglec-11   Decreased expression in ovarian fibroblasts       Strong expression in chimpanzee ovarian fibroblasts                         [@evaa125-B102]                                            Unknown
  Siglec-13   Deleted in humans                                 Expressed in chimpanzee monocytes                                           [@evaa125-B101]                                            Unknown
  Siglec-13   Deleted in humans                                 Expressed in chimpanzee epithelium                                          Present study ([fig. 3*B*](#evaa125-F3){ref-type="fig"})   Unknown
  Siglec-14   Polymorphic expression in amniotic epithelium     Not expressed in chimpanzee amniotic epithelium                             [@evaa125-B3]                                              Intrauterine infections with Group B *Streptococcus*
  Siglec-16   Polymorphic expression in brain microglia         Not expressed in microglia of chimpanzee and gorilla                        [@evaa125-B44]                                             *Escherichia coli* K1 meningitis in neonates and infants
  Siglec-17   No protein expression                             Expressed in natural killer cells of chimpanzee, gorilla, and orangutan     [@evaa125-B101]                                            Unknown

Discussion
==========

Recent availability of sequences of many modern human genomes (1000 Genomes Project Consortium et al. 2015), archaic hominins ([@evaa125-B39]; [@evaa125-B79], [@evaa125-B80]; [@evaa125-B62], [@evaa125-B63]; [@evaa125-B22]; [@evaa125-B77]; [@evaa125-B82]; [@evaa125-B56]; [@evaa125-B89]), and great apes ([@evaa125-B76]; [@evaa125-B106]; [@evaa125-B28]) provides a tool for understanding the role of evolution in shaping genetic architecture and allowing us to identify the genetic basis of phenotypic traits of various species ([@evaa125-B40]; [@evaa125-B17]; [@evaa125-B94]; [@evaa125-B21]). Our earlier studies noted multiple genomic changes affecting sialic acid biology, and we suggested the possibility of a hotspot in humans affecting these pathways compared with our closest evolutionary relatives ([@evaa125-B5]). However, the limited availability of annotated and high coverage genomes at the time left the question unresolved, and our suggestion has been recently tested by others ([@evaa125-B65]), who could not find evidence for strong selective sweeps in current human populations. We herewith show that apart from the fixed *CMAH* null mutation and increased expression of *ST6GAL1* ([@evaa125-B36]), most of the human-specific changes affecting sialic acid biology are found in the *SIGLEC* gene cluster on chromosome 19, and that although great ape genomes do not show many changes in this cluster, almost all the human changes are also found in archaic genomes of Neanderthals and Denisovans ([@evaa125-B79]; [@evaa125-B22]; [@evaa125-B77]; [@evaa125-B89]; [@evaa125-B13]). In keeping with this overall conclusion, there was no evidence for strong selective pressure in this cluster after ∼0.6 Ma, when the human lineage diverged from Neanderthal--Denisovan common ancestor.

With regard to timing and order of changes, the most likely possibility is that the *CMAH* mutation first dramatically altered sialic acids throughout the body, possibly initiating a series of events that resulted in *SIGLEC* cluster changes. The complex and dynamic relationships between host and pathogens is often characterized by the Red Queen hypothesis, whereby slowly evolving hosts have to keep changing to keep pace with the pressure exerted by more rapidly evolving pathogens. Sialic acids form one primary interface, "the molecular frontier" in this evolutionary arms race. The loss-of-function of *CMAH* and the changes in *ST6GAL1* expression undoubtedly led to multiple alterations of human--pathogen interactions. The direct consequence was the change in human cell surfaces, leading to overexpression of Neu5Ac, escaping Neu5Gc-specific pathogens, and favoring human pathogens that interact with Neu5Ac. There are many other known and possible biological consequences of human Neu5Gc loss ([@evaa125-B96]; [@evaa125-B70]), including protection from various Neu5Gc-recognizing pathogens such as malaria caused by *Plasmodium reichenowi* in African great apes ([@evaa125-B59]), *Escherichia coli* K99 gastroenteritis ([@evaa125-B57]), transmissible gastroenteritis coronavirus ([@evaa125-B87]), and simian virus 40 ([@evaa125-B19]). Conversely, *CMAH* loss likely made humans susceptible to Neu5Ac-preferring pathogens such as *Vibrio cholerae* (causative agent of the human-specific disease cholera) ([@evaa125-B4]) and typhoid fever caused by a secreted bacterial toxin that preferentially recognizes Neu5Ac ([@evaa125-B30]). Another human-specific pathogen *Streptococcus pneumoniae* recognizes free Neu5Ac released from human cells by its secreted sialidase ([@evaa125-B47]). Yet another secondary consequence appears to have been the evolution of pathogens that express Neu5Ac on their surfaces as a way to engage CD33-related Siglecs and downregulate innate immune responses in the human host. Again, the existence of many human-specific pathogens that display Neu5Ac supports this scenario ([@evaa125-B6]). For example, Group B *Streptococcus* type III, interacts with Siglec-9 through sialylated CPS and inhibits inflammatory response by neutrophils ([@evaa125-B20]). Likewise, nontypeable *Haemophilus influenzae* expressing sialic acid on its lipooligosaccharide binds to Siglec-5 and reduces cytokine production by myeloid cells ([@evaa125-B9]), and the *E. coli* K1 strain that causes meningitis in neonates and infection in urinary tract, engages Siglec-11, and escapes killing ([@evaa125-B46]). Also, as expected, nonhuman primate Siglec-9 prefers binding to Neu5Gc, whereas human Siglec-9 prefers binding to Neu5Ac ([@evaa125-B91]). Likewise, human Siglec-5 and CD33 prefer binding to Neu5Ac, compared with the baboon CD33, which strongly prefers Neu5Gc ([@evaa125-B74]). These findings imply that Siglecs underwent adaptation in new environments to "catch up" with the changes in human sialome caused by the hominin *CMAH* mutation. Some human Siglecs still prefer binding to Neu5Gc ([@evaa125-B6]), perhaps due to incomplete adaptation to the derived, human Neu5Ac-dominant sialome.

Although these genomic changes are ancient, evidence also suggests that existing human polymorphisms are associated with several diseases such as Chronic obstructive pulmonary disease, asthma, Alzheimer's disease, and meningitis ([@evaa125-B108]; [@evaa125-B37]; [@evaa125-B3]; [@evaa125-B85]). In addition, human Siglec-XII and chimpanzee Siglec12 are expressed on macrophages and luminal epithelia ([@evaa125-B64]). However, human Siglec-XII harbors a universal mutation (R122C) that makes the protein unable to recognize sialic acid. Interestingly, chimpanzee Siglec12 and human Siglec-XII with its arginine experimentally restored strongly prefer Neu5Gc ([@evaa125-B64]). These results suggest a scenario where Siglec-12 lost an endogenous ligand and is thus being eliminated from the population.

Prior studies have reported human-specific Siglec expression changes in placenta (Siglec-6) ([@evaa125-B16]), brain microglia (CD33/Siglec11/16) ([@evaa125-B44]; [@evaa125-B85]), amniotic epithelium (Siglec-5/14) ([@evaa125-B3]), ovarian fibroblasts (Siglec11/16) ([@evaa125-B102]), and NK cells (Siglec-17) ([@evaa125-B101]). We here add to these expression differences by showing that Siglec-7 is upregulated in human but not chimpanzee pancreatic islets, and that the *SIGLEC13* deletion resulted in a loss of Siglec-13 expression from human epithelia. Many of these expression changes could represent secondary consequences of multiple genomic changes that occurred in this gene cluster earlier in the hominin lineage. Overall, it is likely that the selective pressures driving all these changes were most prominent sometime after the split from the common ancestor of human and chimpanzee, but before the split from the Human--Neanderthal--Denisovan common ancestor.

Taken together, our data suggest that innate immune encounters with pathogens markedly altered hominin Siglec biology between 0.6 and 2 Ma, potentially affecting human evolution. Notably, this is the time period when a variety of changes were occurring in genus *Homo*, including exploration of new habitats ([@evaa125-B104]; [@evaa125-B88]; [@evaa125-B29]), striding bipedalism and running ([@evaa125-B14]; [@evaa125-B58]), and scavenging and hunting, involving butchery of animal carcasses with stone tools ([@evaa125-B88]; [@evaa125-B69]; [@evaa125-B60]; [@evaa125-B83]; [@evaa125-B42]; [@evaa125-B11]), activities that may have increased risk of injury, novel infections, and use of fire ([@evaa125-B90]). In this regard, it is also interesting that human-like elimination of *Cmah* in mice enhances running ability ([@evaa125-B71]) as well as macrophage activation ([@evaa125-B72]).
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